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Improvement in Erythropoieis-stimulating Agent-induced Pure 
Red-cell Aplasia by Introduction of Darbepoetin-α When the 
Anti-erythropoietin Antibody Titer Declines Spontaneously
Anti-erythropoietin antibodies usually cross-react with all kinds of recombinant 
erythropoietins; therefore, erythropoiesis-stimulating agent (ESA)-induced pure red-cell 
aplasia (PRCA) is not rescued by different ESAs. Here, we present a case of ESA-induced 
PRCA in a 36-yr-old woman with chronic kidney disease, whose anemic condition 
improved following reintroduction of darbepoetin-α. The patient developed progressive, 
severe anemia after the use of erythropoietin-α. As the anemia did not improve after the 
administration of either other erythropoietin-α products or erythropoietin-β, all ESAs were 
discontinued. Oxymetholone therapy failed to improve the transfusion-dependent anemia 
and a rechallenge with ESAs continuously failed to obtain a sustained response. However, 
her anemia improved following reintroduction of darbepoetin-α at 3 yr after the initial 
diagnosis. Interestingly, anti-erythropoietin antibodies were still detectable, although their 
concentration was too low for titration. In conclusion, darbepoetin-α can improve ESA-
induced PRCA when the anti-erythropoietin antibody titer declines and its neutralizing 
capacity is lost. 
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CASE REPORT
Nephrology
INTRODUCTION
Pure red-cell aplasia (PRCA) is a disorder of erythropoiesis that 
leads to sudden-onset, progressive and severe anemia. Since 
1998, there have been cases of recombinant human erythropoi-
etin (rEPO) antibody-associated PRCA in patients with chronic 
kidney disease who receive subcutaneous treatment with rEPOs. 
In general, patients developing erythropoiesis-stimulating agent 
(ESA)-induced PRCA should not be treated with another ESA, 
because anti-EPO antibodies will certainly cross-react with the 
ESA and can induce systemic adverse reactions (1, 2). However, 
some case reports have described patients with ESA-induced 
PRCA who recovered responsiveness to the same or different 
ESA after immunosuppressive therapy. A rechallenge with the 
same or another ESA has been proposed after patients become 
free off the antibodies following immunosuppressive therapy 
or renal transplantation (3, 4). Herein, we report a case of ESA-
induced PRCA in a 36-yr-old woman with chronic kidney dis-
ease caused by immunoglobulin A nephropathy (5), whose con-
dition improved after reintroduction of darbepoetin-α when 
the anti-EPO antibody titer declined without further immuno-
suppression.
 CASE REPORT
A 36-yr-old female patient was admitted for severe anemia in 
July 2002. She had been diagnosed with chronic kidney disease 
caused by immunoglobulin A (IgA) nephropathy. In October 
2000, she began to receive rEPO therapy with Epokine (CJ Corp, 
Seoul, Korea), an EPO-α product, at a dose of 4,000 IU/week on 
subcutaneous (SC) route for anemia. Her hemoglobin (Hb) 
level was maintained at 10–12 g/dL before hemodialysis. In 
January 2002, she was started on hemodialysis, and her Hb lev-
el was maintained at 8–10 g/dL under EPO-α treatment at a 
dose of 3,000-6,000 IU/week. Eleven months after the start of 
hemodialysis, her Hb level dropped to 5.3 g/dL, although she 
was treated with rEPO-α at a dose of 12,000 IU/week. Even with 
the cumulative ESA dose of 224,000 IU over 26 months, her 
anemia did not improve. Therefore, she was transfused with 
two units of packed red blood cells every three weeks to main-
tain her Hb level despite the ESA treatment (12,000–15,000 IU/
week). Meanwhile, she received three types of rEPO-α products 
(Epokine, Espogen [LG Life Sciences, Seoul, Korea], and Epo-
ron [Dong-A Pharmaceutical Co., Ltd., Seoul, Korea]) and one 
rEPO-β (Recormon [Roche, Basel, Switzerland]) product tran-Lee H, et al.  •  Darbepoetin-α Improves ESA-induced PRCA 
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siently, but her anemia did not improve at all. 
  Initial laboratory test values on admission were as follows: 
leukocyte count, 4,610 cells/µL; Hb, 5.4 g/dL; platelet count, 
113,000 cells/µL; reticulocytes, 0.27%; total iron binding capac-
ity, 220 μg/dL (39.38 μM/L); ferritin, 1,760 μg/L; iron, 201 μg/dL 
(35.98 μM/L); parathyroid hormone, 23 ng/L; blood urea nitro-
gen, 83 mg/dL (29.63 mM/L); creatinine, 12.3 mg/dL (1,087.32 
μM/L); C-reactive protein, 0.75 mg/dL. Serologic tests for hepa-
titis viruses, cytomegalovirus, Epstein-Barr virus, human im-
munodeficiency virus, and parvovirus B19 were all negative. 
Thoracic computed tomographic scans or abdominal sonogra-
phy showed no evidence of an abnormal mass such as thymo-
ma or lymphoma. Bone marrow examination showed reduced 
cellularity (0–20%) and severe erythroid hypoplasia, whereas 
thrombopoiesis was in the low normal range and granulopoie-
sis was normal, findings consistent with PRCA (Fig. 1). 
  In June 2003, anti-EPO antibodies were screened by compe-
tition enzyme-linked immunoassay (ELISA). The result of ELISA 
showed 1.9 times higher antibody titer in patients serum com-
pared with in control serum, and ESA treatment was discontin-
ued. The PRCA did not respond to oxymetholone treatment 
from June 2003 to July 2003. Although we considered immune-
suppressive therapies, she refused to receive the treatments. In 
September 2003, the antibody was also identified by radioim-
Fig. 1. Bone marrow biopsy findings. (A) Bone marrow section, The cellularity is 0-20% which is hypocellular for age. Trilineage hematopoiesis is markedly decreased, and the 
decrease of erythropoiesis is remarkable. Plasma cells, lymphocytes and eosinophils are unremarkable. Foreign cells and granulomata are absent, H&E stained, ×100. (B) A 
megakaryocyte and myeloid precursor cells are observed, but no erythroid precursor cells are observed, H&E stained, ×1,000.
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Fig. 2. Clinical course of the patient by time. The gray line is a schematic representation of the patient’s hemoglobin (Hb) levels (conversion factor from g/dL to g/L, ×10) from 
June 2000 to April 2009. One red triangle means transfusion of two units of packed red blood cells. Hemodialysis (HD) was initiated in January 2002. Oxymetholone therapy 
was given from June 2003 to July 2003. The double-headed arrows below the graph indicate the durations of erythropoiesis-stimulating agent use, represented by the 
following colors: green arrow, Epokine; blue arrows, Espogen; violet arrows, Recormon; yellow arrows, Aranesp.Lee H, et al.  •  Darbepoetin-α Improves ESA-induced PRCA 
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munoprecipitation assay, their binding capacity was 5.6 IU/mL. 
In the neutralizing capacity test, her serum showed complete 
inhibition of colony formation by normal marrow cells when 
stimulated by 0.5 IU of rEPO-α in an in vitro bioassay. 
  After then, she remained transfusion-dependent, Espogen was 
restarted from January 2004, but there was no response. After 
she was switched to Recormon on SC route, the transfusion re-
quirement decreased and her anemia showed slight improve-
ment. However, her Hb level decreased to 5.3 g/dL again in April 
2005. Despite the increased dose of Recormon up to 15,000 IU/
week, her Hb level did not recover. In June 2005, the patient was 
started on another type of ESA therapy, 40 µg/week of Aranesp 
(darbepoetin-α, Amgen Inc., San Francisco, CA, USA) subcuta-
neously, but her anemia did not seem to improve. Although 
darbepoetin-α was replaced with Recormon, there was a big 
decline in her Hb level again in April 2006. Later, darbepoetin-α 
(50 mcg/week) was reintroduced, following which her Hb level 
started to recover slowly and she did not require transfusions 
from August 2006. Her Hb level increased up to 12.1 g/dL under 
20 µg/week of darbepoetin-α treatment in December 2006. 
  In July 2007, anti-EPO antibodies were still detectable by ra-
dioimmunoprecipitation testing, but the concentration was too 
low for titration. Similarly, biosensor immunoassay (Biacore 
3000; GE Healthcare Life-science Corp., UK) detected antibod-
ies against both EPO-α and darbepoetin-α, but their titers were 
below the quantifiable levels of 80 ng/mL and 100 ng/mL, re-
spectively. The neutralizing capacity was not detected in an in 
vitro bioassay. Until now, the patient is on subcutaneous dar-
bepoetin-α treatment and the Hb level is maintained at around 
9–11 g/dL (Fig. 2). 
DISCUSSION
There is no consensus on the optimal therapy for ESA-induced 
PRCA. Most often, withdrawal of all kinds of ESAs has been rec-
ommended, because there is substantial cross-reactivity among 
the ESAs, including darbepoetin-α and endogenous EPO (1, 6). 
Further, immunosuppressive therapy is usually required to low-
er the anti-EPO antibodies. According to the RADAR Project (3), 
the recovery rates from PRCA are 2% without immunosuppres-
sive therapy but reach 52% after immunosuppressive therapy 
and 95% after kidney transplantation. Cyclosporine, corticoste-
roids, and cyclophosphamide are widely used, but other im-
mune-modulating measures including intravenous immuno-
globulins, rituximab (7), and plasma exchange with immuno-
adsorption (8) can also be tried. Although patients with ESA-
associated PRCA are unlikely to respond to treatment with other 
ESAs, a rechallenge using an alternative ESA has been success-
ful in some cases where the anti-EPO antibody titer declined to 
below or around its lower detection limit after treatment with 
immunosuppressants (7, 9-13). In fact, PRCA patients with chron-
ic kidney disease are persistently exposed to the causative anti-
gen even after the removal of exogenous ESAs because a small 
amount of endogenous EPO is produced continuously in these 
patients. Therefore, withdrawal of all kinds of ESAs might not be 
the absolute solution in the treatment of ESA-induced PRCA, 
and an ESA rechallenge is recommended for patients with ESA-
induced PRCA when the anti-EPO antibody titer is low (4). 
  Most of the patients showing a good response to an ESA re-
challenge had experienced a successful response to immuno-
suppressive therapy before the rechallenge. However, our pa-
tient did not show an adequate response to short-term oxy-
metholone treatment, because her anemia was not corrected 
and the anti-EPO antibody titer was still high. Instead, the EPO 
antibody titer seemed to decline spontaneously over time. A 
similar case has been reported in which darbepoetin-α rescued 
ESA-induced PRCA successfully without immunosuppressive 
therapy in spite of the presence of anti-EPO antibodies; inter-
estingly, the anti-EPO antibody titer declined spontaneously, as 
in our case, when darbepoetin-α treatment was attempted (13). 
Another case showed darbepoetin-α was rechallenged success-
fully when anti-EPO antibody titer remained still high; however, 
several immunesuppressive regimens were successively tried 
in that case (14). 
  Different glycosylation patterns of darbepoetin-α might re-
duce the affinity of anti-EPO antibodies toward darbepoetin-α 
compared with that toward other ESAs. Differences in ESA for-
mulation might also contribute to the variable immunogenicity 
of different ESAs. For example, the exposure-adjusted PRCA in-
cidence per 10,000 chronic kidney disease patients was 2.7 with 
subcutaneous human serum albumin (HSA)-free Eprex, whereas 
it was 0.2 with subcutaneous HSA-containing Eprex or epoetin-β 
(15). It is assumed that the relatively lower affinity of anti-EPO 
antibodies toward darbepoetin-α can overcome the inhibitory 
effects of these antibodies, especially when their titer declines 
(13). Similarly, novel ESAs such as Hematide (Affymax Inc., Palo 
Alto, CA, USA), a pegylated synthetic peptide, can also be admin-
istered instead of darbepoietin-α, because anti-EPO and anti-
Hematide antibodies did not cross-react with Hematide and 
EPO, respectively, in an PRCA experimental model (16). Fur-
ther studies are, however, needed to identify the precise epit-
opes of various ESAs interacting with EPO receptors in order to 
support our hypothesis.
  In summary, we have reported a rare case of ESA-induced 
PRCA that improved successfully following the reintroduction 
of darbepoetin-α without further immunosuppression in the 
presence of a low level of anti-darbepoetin-α antibodies. This 
case suggests that darbepoetin-α can be used in a rechallenge 
to treat ESA-induced PRCA when the anti-EPO antibody titer 
declines and loses its neutralizing capacity.Lee H, et al.  •  Darbepoetin-α Improves ESA-induced PRCA 
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